ERBB2 and cancer: CDK4/6 inhibitors (CDK4/6i) have been effectively utilized in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic or advanced BC patients, demonstrating the ability to delay cancer progression and enhance patient quality of life.